Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500149 | 0.92 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL468343 | 0.92 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL468245 | 0.88 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL500273 | 0.88 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL500450 | 0.88 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL468312 | 0.88 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL683517 | 0.85 | PTPRB (0.85) | PTPRBPTPN11 | |
| SCHEMBL468305 | 0.84 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL500679 | 0.84 | PTPRB (1.00) | PTPRBPTPN11 | |
| SCHEMBL500258 | 0.84 | PTPRB (0.80) | PTPRBPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231799-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2019-08-01 | — | — | US | disclosed |
| EP-3293182-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Aerpio Therapeutics, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2803663-A1 | Human protein tyrosine phosphatase inhibitors and their pharmaceutical use | Aerpio Therapeutics Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231799-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885PTPN11 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.